{
    "clinical_study": {
        "@rank": "77131", 
        "arm_group": [
            {
                "arm_group_label": "BCD-021 (CISC BIOCAD)", 
                "arm_group_type": "Experimental", 
                "description": "BCD-021 is a product code for bevacizumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-021 in combination with carboplatin and paclitaxel. BCD-021 will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each course). Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml\u00d7min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1."
            }, 
            {
                "arm_group_label": "Avastin (F. Hoffmann-La Roche Ltd)", 
                "arm_group_type": "Active Comparator", 
                "description": "In this arm patients will receive 6 courses of treatment with Avastin in combination with carboplatin and paclitaxel. Avastin will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks on Day 1. Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml\u00d7min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1."
            }
        ], 
        "brief_summary": {
            "textblock": "BCD-021-02 is a double-blind randomized clinical trial comparing efficacy of BCD-021 (INN:\n      bevacizumab) and paclitaxel + carboplatin to Avastin and paclitaxel + carboplatin in\n      inoperable or advanced non-squamous NSCLC patients with pharmacokinetics substudy. The\n      purpose of the study is to demonstrate the non-inferiority of efficacy and safety of BCD-021\n      compared to Avastin. Also study includes pharmacokinetics assessment."
        }, 
        "brief_title": "A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent;\n\n          -  Newly diagnosed histologically or cytologically confirmed NSCLC excluding squamous\n             NSCLC (mixed cancer types should be classified according to the prevalent cell type);\n\n          -  IIIb or IV stage of NSCLC (TNM classification version 6);\n\n          -  Age \u2265 18 years and age \u2264 70 years (both inclusive);\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2, (not\n             declining within 2 weeks prior to the first dose of investigational product);\n\n          -  Life expectancy - 12 weeks or more from the moment of randomization;\n\n          -  Presence of at least 1 measurable tumour with a size not less than 1 cm (revealed\n             with CT slice thickness not more than 5 mm), as defined by modified Response\n             Evaluation Criteria in Solid Tumors (RECIST) criteria (specifically, no ascites,\n             pleural, or pericardial effusions, osteoblastic bone metastases, or carcinomatous\n             lymphangitis of the lung as only lesion;\n\n          -  Patients should be able to follow the Protocol procedures (according to\n             Investigator's assessment);\n\n          -  Patients must implement reliable contraceptive measures during all the study\n             treatment, starting 4 weeks prior to the administration of the first dose of\n             investigational product until 6 months after the last dose of investigational\n             product. This requirement does not apply to participants who have undergone surgical\n             sterilization, or patients who are postmenopausal (documented) for the past 2 years.\n             Reliable contraceptive measures include two methods of contraception, including one\n             barrier method\n\n        Exclusion Criteria:\n\n          -  Squamous NSCLC;\n\n          -  Proven coagulopathy, clinically significant hemorrhage in the past including nasal\n             hemorrhage;\n\n          -  absolute neutrophil count <1500/mm3;\n\n          -  Platelets <100 000/mm3;\n\n          -  Hemoglobin < 90 g/L;\n\n          -  Creatinine level \u22651.5 mg/dL;\n\n          -  Bilirubin level \u22651.5 \u00d7 upper limit of normal (ULN);\n\n          -  Aspartate-aminotransferase(AST) and alanine-aminotransferase (ALT) levels \u22652.5 \u00d7 ULN\n             (\u22655 \u00d7 ULN for patients with liver metastases);\n\n          -  Alkaline phosphatase level \u22655 \u00d7 ULN;\n\n          -  Current therapeutic anticoagulation treatment, aspirin (more than 325 mg/day),\n             nonsteroidal anti-inflammatory drugs, antiplatelet agents or protracted treatment\n             with these drugs  less than 1 month before entering the study;\n\n          -  Uncontrolled hypertension comprising all cases of arterial hypertension when no\n             decrease in blood pressure could be achieved despite treatment with a combination of\n             3 antihypertensive drugs including one diuretic and non-medical correction methods\n             (low salt diet, physical exercise);\n\n          -  Previous anticancer therapy of metastatic NSCLC;\n\n          -  Radiation or hormone therapy within 21 days prior to randomization;\n\n          -  Major surgery 28 days before inclusion into the study;\n\n          -  Previous antiangiogenic therapy;\n\n          -  Hypersensitivity to taxanes, platinum agents, recombinant murine proteins, contrast\n             agents, premedication agents specified by Protocol (dexamethasone, diphenhydramine,\n             ranitidine) or excipients of investigational products;\n\n          -  NSCLC metastases in   central nervous system excluding metastases non-progressing\n             without glucocorticosteroids within 4 weeks before inclusion into the trial;\n\n          -  Cardiovascular system pathology (CHF stage III-IV according to New York Heart\n             Association (NYHA) classification);\n\n          -  Pregnancy or lactation;\n\n          -  Conditions limiting patient's adherence to Protocol requirements (dementia,\n             neurologic or psychiatric disorders, drug addiction, alcoholism and others);\n\n          -  Stage II-IV neuropathy according to Common Terminology Criteria for Adverse Events\n             (CTCAE) v.4.0;\n\n          -  Simultaneous participation in other clinical trials, previous participation in other\n             clinical trials within 30 days before entering into the trial, previous participation\n             in the same trial;\n\n          -  Any other concomitant cancer revealed within 5 years prior to screening, except\n             curatively treated intraductal carcinoma in situ, curatively treated cervical\n             carcinoma in situ or curatively treated basal cell or squamous cell carcinoma;\n\n          -  Acute or active chronic infections;\n\n          -  Hepatitis C virus, hepatitis B virus, HIV, or syphilis infections;\n\n          -  Obstacles in intravenous administration of study drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "214", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01763645", 
            "org_study_id": "BCD-021-02"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "BCD-021 (CISC BIOCAD)", 
                    "Avastin (F. Hoffmann-La Roche Ltd)"
                ], 
                "description": "Patients will receive 6 courses of bevacizumab in combination with carboplatin and paclitaxel. Bevacizumab will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Avastin", 
                    "BCD-021"
                ]
            }, 
            {
                "arm_group_label": [
                    "BCD-021 (CISC BIOCAD)", 
                    "Avastin (F. Hoffmann-La Roche Ltd)"
                ], 
                "description": "Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion on Day 1 of each 3-week course (6 courses totally)", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxacad"
            }, 
            {
                "arm_group_label": [
                    "BCD-021 (CISC BIOCAD)", 
                    "Avastin (F. Hoffmann-La Roche Ltd)"
                ], 
                "description": "Carboplatin will be administered (AUC 6 mg/ml\u00d7min) as 15 - 30 min intravenous infusion just after paclitaxel on Day 1 of each 3-week course (6 courses totally).", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bevacizumab", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "NSCLC", 
            "bevacizumab", 
            "pharmacokinetics"
        ], 
        "lastchanged_date": "January 13, 2014", 
        "link": {
            "url": "http://www.biocad.ru"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brest", 
                        "country": "Belarus"
                    }, 
                    "name": "Brest Regional Clinical Dispensary"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gomel", 
                        "country": "Belarus"
                    }, 
                    "name": "Gomel Regional Clinical Oncology Dispensary"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grodno", 
                        "country": "Belarus"
                    }, 
                    "name": "Grodno Regional Clinical Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vitebsk", 
                        "country": "Belarus"
                    }, 
                    "name": "Vitebsk Regional Clinical Oncology Dispensary"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangalore", 
                        "country": "India", 
                        "zip": "560027"
                    }, 
                    "name": "HCG Bangalore Institute of Oncology"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangalore", 
                        "country": "India", 
                        "zip": "560099"
                    }, 
                    "name": "Narayana Hrudayalaya Hospitals"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangalore", 
                        "country": "India", 
                        "zip": "560054"
                    }, 
                    "name": "M.S.Ramaiah Memorial Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Arkhangelsk", 
                        "country": "Russian Federation", 
                        "zip": "163045"
                    }, 
                    "name": "Arkhangelsk District Clinical Oncology Dispensary"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chelyabinsk", 
                        "country": "Russian Federation"
                    }, 
                    "name": "State-financed Health Institution \"Chelyabinsk Region Clinical Oncology Dispansary\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chelyabinsk", 
                        "country": "Russian Federation", 
                        "zip": "454000"
                    }, 
                    "name": "Non-governmental Healthcare Institution \"Railway Clinical hospital on the Chelyabinsk Station of JSC Russian Railways\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kursk", 
                        "country": "Russian Federation", 
                        "zip": "305035"
                    }, 
                    "name": "State Healthcare Facility \"Kursk Regional Oncology Dispensary\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "194044"
                    }, 
                    "name": "Federal State Institution \"Moscow Institute of Cancer Research named after P.A. Hertsen\" Ministry of Health of Russian Federation"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "115478"
                    }, 
                    "name": "Institution of Russian Academy of Medical Sciences \"Russian Cancer Research Center named after N.N. Blokhin\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow Region", 
                        "country": "Russian Federation", 
                        "zip": "143423"
                    }, 
                    "name": "State Health Institution of Moscow \"Moscow City Oncology Hospital #62 of Moscow Board of Health\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Murmansk", 
                        "country": "Russian Federation", 
                        "zip": "183047"
                    }, 
                    "name": "Murmansk Regional Oncology Dispensary"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nizhny Novgorod", 
                        "country": "Russian Federation", 
                        "zip": "603006"
                    }, 
                    "name": "Nizhny Novgorod Region State Budgetary Healthcare Facility \"Clinical Diagnostics Center\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nizhny Novgorod", 
                        "country": "Russian Federation"
                    }, 
                    "name": "State Healthcare Facility \"Nizhny Novgorod Regional Oncology Dispensary\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Novosibirsk", 
                        "country": "Russian Federation", 
                        "zip": "630047"
                    }, 
                    "name": "City Clinical Hospital \u21161"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orel", 
                        "country": "Russian Federation", 
                        "zip": "302020"
                    }, 
                    "name": "Regional State Health Institution \"Orlov Oncology Dispansary\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Penza", 
                        "country": "Russian Federation", 
                        "zip": "440071"
                    }, 
                    "name": "State Health Institution \"Region Oncology Dispansary\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Perm", 
                        "country": "Russian Federation", 
                        "zip": "614066"
                    }, 
                    "name": "Perm Region Oncology Dispensary"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rostov-on-Don", 
                        "country": "Russian Federation", 
                        "zip": "314019"
                    }, 
                    "name": "Federal Government Budgetary Institution \"Rostov Institute of Cancer Research\" of Ministry of Health of Russian Federation"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "197022"
                    }, 
                    "name": "Saint Petersburg City Clinical Oncology Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Samara", 
                        "country": "Russian Federation", 
                        "zip": "443031"
                    }, 
                    "name": "State-financed Health Institution \"Samara Region Clinical Oncology Dispansary\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sochi", 
                        "country": "Russian Federation", 
                        "zip": "354057"
                    }, 
                    "name": "Oncology Dispensary 2"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "197022"
                    }, 
                    "name": "St. Petersburg State Medical University n.a. I. P. Pavlov"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "197758"
                    }, 
                    "name": "St. Petersburg Research and Practice Center for Secondary Care in Oncology"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St.Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "197758"
                    }, 
                    "name": "N.N.Petrov Oncology Research Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St.Petersburg", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Russian scientific center of radiology and surgery technologies"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St.Petersburg", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Military Medical Academy named after S.M. Kirov"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stavropol", 
                        "country": "Russian Federation", 
                        "zip": "355047"
                    }, 
                    "name": "State-financed Health Institution \"Stavropol Region Clinical Oncology Dispansary\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Volgograd", 
                        "country": "Russian Federation", 
                        "zip": "400138"
                    }, 
                    "name": "Volgograd District Oncology Dispensary \u21161"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Volgograd", 
                        "country": "Russian Federation", 
                        "zip": "404130"
                    }, 
                    "name": "Volgograd Regional Oncology Dispensary \u21163"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Voronezh", 
                        "country": "Russian Federation", 
                        "zip": "394000"
                    }, 
                    "name": "State Health Institution \"Voronezh Region Clinical Oncology Dispansary\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Donetsk", 
                        "country": "Ukraine"
                    }, 
                    "name": "Donetsk Regional Antitumor Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Donetsk", 
                        "country": "Ukraine"
                    }, 
                    "name": "Donetsk City Oncology Dispensary"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kharkiv", 
                        "country": "Ukraine"
                    }, 
                    "name": "Kharkiv Regional Clinical Oncology Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kryvyi Rih", 
                        "country": "Ukraine"
                    }, 
                    "name": "Kryvyi Rih Oncology Dispensary"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lviv", 
                        "country": "Ukraine"
                    }, 
                    "name": "Lviv State Regional Cancer Diagnostic and Treatment Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Makiivka", 
                        "country": "Ukraine"
                    }, 
                    "name": "City Hospital \u2116 2"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Poltava", 
                        "country": "Ukraine"
                    }, 
                    "name": "Poltava Regional Clinical Oncology Dispensary"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Uzhhorod", 
                        "country": "Ukraine"
                    }, 
                    "name": "Zakarpatskyi Clinical Oncology Dispensary"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vinnytsia", 
                        "country": "Ukraine"
                    }, 
                    "name": "Vinnytsia Regional Clinical Oncology Dispensary"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zaporizhia", 
                        "country": "Ukraine"
                    }, 
                    "name": "Zaporizhia Regional Clinical Oncology Dispensary"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belarus", 
                "India", 
                "Russian Federation", 
                "Ukraine"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "International Multicenter Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of BCD-021 (CJSC BIOCAD, Russia) and Paclitaxel + Carboplatin to Avastin\u00ae (F. Hoffmann-La Roche Ltd, Switzerland) and Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-small-cell Lung Cancer (NSCLC) Patients", 
        "overall_contact": {
            "email": "biryulin@biocad.ru", 
            "last_name": "Andrey Biryulin, MD", 
            "phone": "+7 (812) 380-49-33", 
            "phone_ext": "925"
        }, 
        "overall_contact_backup": {
            "email": "filonov@biocad.ru", 
            "last_name": "Olga Filon, MD", 
            "phone": "+7 (812) 380-49-33", 
            "phone_ext": "916"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of the Russian Federation", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "primary outcome measure for efficacy evaluation", 
                "measure": "Overall response rate", 
                "safety_issue": "No", 
                "time_frame": "Day 127"
            }, 
            {
                "description": "primary outcome measure for pharmacokinetics (PK) substudy", 
                "measure": "Area under the curve after the first test drug administration", 
                "safety_issue": "No", 
                "time_frame": "up to Day 22, after the first bevacizumab administration (time points for blood samples: 0 h 1.5 h, 3 h, 4.5 h, 6 h, 24 h, 96 h, 168 h, 336 h and 504 h)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01763645"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "secondary outcome measure for efficacy evaluation", 
                "measure": "Complete response rate", 
                "safety_issue": "No", 
                "time_frame": "Day 127"
            }, 
            {
                "description": "secondary outcome measure for efficacy evaluation", 
                "measure": "Partial response rate", 
                "safety_issue": "No", 
                "time_frame": "Day 127"
            }, 
            {
                "description": "secondary outcome measure for efficacy evaluation", 
                "measure": "Stabilization rate", 
                "safety_issue": "No", 
                "time_frame": "Day 127"
            }, 
            {
                "description": "secondary outcome measure for efficacy evaluation", 
                "measure": "Progression rate", 
                "safety_issue": "No", 
                "time_frame": "Day 127"
            }, 
            {
                "description": "secondary outcome measure for safety evaluation", 
                "measure": "Relative number (%) of chemotherapy cycles, postponed due to adverse events (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 127"
            }, 
            {
                "description": "secondary outcome measure for safety evaluation", 
                "measure": "Treatment discontinuation rate due to AE", 
                "safety_issue": "Yes", 
                "time_frame": "Day 127"
            }, 
            {
                "description": "Secondary outcome measure for immunogenicity assessment", 
                "measure": "Occurrence and titer of anti-bevacizumab antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 (before the drug administration), Day 15, 64 and 127"
            }, 
            {
                "description": "secondary outcome measure for PK substudy", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 22"
            }, 
            {
                "description": "secondary outcome measure for PK substudy", 
                "measure": "Tmax", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 22"
            }, 
            {
                "description": "secondary outcome measure for PK substudy", 
                "measure": "T1/2", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 22"
            }, 
            {
                "description": "secondary outcome measure for safety evaluation", 
                "measure": "AE incidence and severity", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 148"
            }, 
            {
                "description": "secondary outcome measure for safety evaluation", 
                "measure": "AEs grade 3-4 incidence", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 148"
            }, 
            {
                "description": "Secondary outcome measure for pharmacokinetics analysis", 
                "measure": "minimal serum bevacizumab concentration", 
                "safety_issue": "No", 
                "time_frame": "Day 22, Day 43, Day 64, Day 85, Day 106, Day 127"
            }
        ], 
        "source": "Biocad", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biocad", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}